Washington, D.C. — September 12, 2019 — International Leaders Summit, a US-based think tank, will host the inaugural US-India Leaders Summit at The National Press Club in Washington, D.C., on September 18, 2019, to advance public policies which strengthen the two nations’ ties on the economic, healthcare, trade and security fronts. Keynote speakers at the summit include Dr. Christiane Hamacher, CEO of Biocon Biologics, a global biopharmaceutical company; Congressmen Michael Bost, Michael Guest and Mike Kelly; Former Congressmen Scott Taylor and Tom Garrett; Natasha Srdoc and Joel Anand Samy, co-founders, International Leaders Summit; Ambassador Amit Kumar, deputy chief of mission, Embassy of India in Washington D.C.; Stephen Renna, chief banking officer, EXIM; Virginia’s State Senator Richard H. Black; Beth Saunders, president, Sanford Saunders Enterprises LLC; Dr. Sampat Shivangi and Dr. Suresh Reddy American Association of Physicians of Indian Origin; Dr. Smita Siddhanti, president, TiE Washington, DC; Dr. Derek Scissors, resident scholar, American Enterprise Institute; Joseph Brodecki, principal partner, Washington, D.C.-based Bernstein Global Wealth Management Group, among other distinguished leaders.
The event’s topics will address America’s healthcare crisis and focus on solutions presented by leaders from India, the U.S. and networks representing 80,000 Indian American physicians. The summit will examine the state of the US-India trade, economic reforms and security challenges impacting both nations. In advancing healthcare reform solutions, the International Leaders Summit is working with the American Association of Physicians of Indian Origin.
“We look forward to the high-level timely discussions with distinguished leaders and decision-makers at the inaugural US-India Leaders Summit in Washington, DC focusing on advancing principled ideas and solutions,” said Natasha Srdoc, MBA, co-founder of the US-based International Leaders Summit. “We take seriously the challenges of 100 million Americans living with diabetes or prediabetes facing the skyrocketing cost of insulin. It is unacceptable that individuals have to ration medical treatment in America today. This event highlights solutions in the fields of healthcare, trade and investments and how synergies between American and Indian entities can solve immediate and long-term challenges.”
“I am delighted to be a part of the US-India Leaders Summit, a forum that can unleash the innovation-led synergy between India and the US, said Christiane Hamacher, CEO, Biocon Biologics. “I am confident that this Summit will strengthen the strategic economic and healthcare partnerships between the two nations. Access and affordability are the two pivotal points around which health economics revolves. The world, including the US, needs innovative and affordable solutions to deliver on the promise of a fundamental ‘Right to Healthcare.’ Biocon Biologics can be an enabling partner for the US to address the grave threat of spiraling healthcare costs for chronic diseases like cancer and diabetes by expanding access to high quality, yet affordable, biosimilars. We have enabled patients across many countries to effectively manage their diabetes at a fraction of the price they pay for originator drugs. As one of the leading insulins players in the world, Biocon is keen to address the unmet patient needs of people with diabetes in the US as well.”
“Four million Indian Americans investing in America’s economy in the areas of education, technology and real estate, and providing patient care, are a natural bridge to building stronger economic, healthcare, and trade partnerships which benefit both the U.S. and India,” said Joel Anand Samy, co-founder, International Leaders Summit. “This win-win concept is a 21st century strategic opportunity to reform the healthcare sector, create jobs and augment economic growth for both nations with a combined population of 1.6 billion people.”
The summit’s agenda also includes panel discussions on critical topics, such as addressing barriers to trade and investments and how a bold US-India trade agreement can boost economic growth for America’s population of 330 million and India’s 1.3 billion citizens.
To learn more about the summit, visit https://ileaderssummit.org/event/the-inaugural-us-india-leaders-summit-washington-dc/
Overview of Organizations:
International Leaders Summit, a US-based think tank, is dedicated to presenting principled public policies and pro-growth solutions based on the foundational rule of law which protects life, liberty and private property. The independent think tank leads a coalition of principled leaders within America and in partnering countries to strengthen the rule of law, advance economic freedom, address healthcare reforms, expand free and fair trade and to secure peace through strength. The Summit builds upon high-level events and meetings in Europe, the Middle East and United States with events hosted at the European Parliament in Brussels, Washington, DC, Jerusalem, London, Ljubljana, Prague and Warsaw.
The US-India Leaders Summit is hosted in partnership with Biocon Biologics, Sanford Saunders Enterprises, American Association of Physicians of Indian Origin and Kam Global Strategies.
Biocon Biologics: Transforming Healthcare, Transforming Lives
Biocon Biologics is a subsidiary of Biocon Ltd, an innovation led global biopharmaceuticals company and India’s first publicly listed biotech enterprise. Biocon Biologics is engaged in developing high quality, affordable biosimilars that can expand access to a cutting edge class of therapies to patients globally. It is the only fully integrated pure play biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions.
The Company is serving patients in U.S., EU, Latin America and Japan through its wide biosimilar portfolio and has gained a broad experience in managing the risks entailed in taking advanced therapies from ‘bench to bedside’ even in the most stringently regulated markets.
As India’s largest biotech enterprise, Biocon’s journey of biologics had started with a novel biologic for head and neck cancer, which has benefitted thousands of patients in India. As a frontrunner in biosimilars, Biocon Biologics is addressing the needs of patients for affordable biologics across many developed and emerging markets through its recombinant human Insulin, Insulin Glargine, biosimilar Trastuzumab and other biopharmaceuticals. Biocon Biologics, through its partner, was the first to obtain an approval for biosimilar Trastuzumab (Ogivri) in the U.S. in 2017 as well as the first to commercialize biosimilar Pegfilgrastim, as Fulphila, in the country. Biocon Biologics’ Insulin Glargine (Semglee) is currently under review by the U.S. regulator.
Biocon Biologics believes that strong partnerships offer enormous opportunities to co-create the future of healthcare, building a patient ecosystem beyond the product, which can transform millions of lives. The Company believes that it can enable the US healthcare system to provide affordable access to diabetes management and cancer care.
Biocon Ltd. has already been making a difference to American patients through its high quality, small molecule APIs since the mid-2000s. Many global pharmaceutical companies use these APIs for producing generic medicines. The Company has also recently commercialized generic formulations of Rosuvastatin, Simvastatin and Atorvastatin under the Biocon label in the U.S., in line with our commitment to enable affordable access to patients.
Laura Kam, Head of Media Relations, International Leaders Summit
Website: International Leaders Summit